New Drugs For Rare Diseases Facing Higher Reimbursement Hurdles
Executive Summary
Drugs and biologics being developed to treat rare diseases, or life-threatening diseases such as cancer and HIV/AIDS are now starting to face the same kind of private payer scrutiny and value-based coverage decisions that were previously reserved for small-molecule drugs entering crowded therapeutic classes